Login to Your Account

Clinic Roundup

Monday, April 2, 2012
The drug ibrutinib (PCI-32765), in development by Pharmacyclics Inc., of Sunnyvale, Calif., and Janssen Research and Development LLC, a unit of Johnson & Johnson, showed significant anti-cancer responses and modest side effects in a pilot trial in the activated B-cell form of diffuse large B-cell lymphoma. Subjects received 560 mg daily until progression of the disease. There were multiple responses and some complete remissions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription